Neumora Therapeutics is trading 8.21% higher at $0.54, with the broader market rebound the likeliest available context—not a confirmed company-specific catalyst.

  • U.S. stocks rallied as investors recovered from the prior week’s selloff.
  • No new company-specific announcement explaining the November 9 move was identified.
  • The company’s investor-relations page lists July 27 as its latest press release.